newsfilter
← Latest News
Business Wire·

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

– Merck to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), the company's subcutaneous anti-PD-1 therapy, for planned STELLAR-316 trial – Exelixis, Inc. (NASDAQ:EXEL) today announced that